BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer.

Pumas-AI Inc, a science-first organization that turns data into life-saving decisions faster, announced today that it is now opening its powerful modeling and simulation software to all global academic institutions and researchers free of charge.

Overlake Medical Center & Clinics this week became the first hospital in the Pacific Northwest region to successfully treat patients for atrial fibrillation utilizing a safer, innovative and minimally invasive treatment technique known as pulsed field ablation.

Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease and previously received Orphan Drug Designation for LP-10 in 2023.

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that it has lifted the previously disclosed1 voluntary pause on screening and randomization of its NATiV3 clinical trial and that sites are resuming screening activities.

argenx SE (Euronext & Nasdaq: ARGX) today announced that eight abstracts, including two oral presentations, featuring clinical trial and real-world data for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in rare autoimmune diseases will be presented at the American Academy of Neurology (AAN) Annual Meeting.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2023 financial results and provided a corporate update.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.

Adagene Inc. announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board.

Neurona Therapeutics announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy, will be presented at the American Academy of Neurology 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.